| atezolizumab based treatment | pembrolizumab based treatment |
| atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus carboplatin plus paclitaxel | pembrolizumab plus SoC |
| squamous - mNSCLC - L1 - all population 4 | | | |
Comparator:
vs carboplatin plus nab-paclitaxel; vs nab-paclitaxel; vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;